MTG2

Across TCGA pan-cancer cohorts, MTG2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of MTG2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MTG2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MTG2 is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

CCRCC, COAD, and LSCC are the cancer types where MTG2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTG2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	−0.811	<.001	11	view →
COAD	Female	II,III,IV	+0.459	<.001	8	view →
LSCC	All	All	+0.192	<.001	8	view →
LUAD	All	All	+0.172	.001	5	view →
PDAC	Male	II,III,IV	−0.482	.019	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

MTG2–CCRCC

Open the CCRCC breakdown →